about
GLP-1 Receptor Agonist Exenatide Increases Capillary Perfusion Independent of Nitric Oxide in Healthy Overweight Men.GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial.Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes.Arm length is associated with type 2 diabetes mellitus in Japanese-Americans.Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trialAdipocytokines as features of the metabolic syndrome determined using confirmatory factor analysisBiliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients.The clinical significance of pancreatic steatosis.Advances in pharmacologic therapies for type 2 diabetes.The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas.GLP-1 based therapies: clinical implications for gastroenterologists.Incretin-based therapy and acute cholecystitis: a review of case reports and EudraVigilance spontaneous adverse drug reaction reporting database.Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment.Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males.Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial.Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial.The effects of GLP-1 based therapies on postprandial haemodynamics: Two randomised, placebo-controlled trials in overweight type 2 diabetes patients.Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial.Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial.Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial.Uncomplicated human type 2 diabetes is associated with meal-induced blood pressure lowering and cardiac output increase.Acute plasma amylase increase after glucagon-like peptide -1 receptor agonist exenatide administration in Type 2 diabetes.Nonalcoholic fatty liver disease is related to nonalcoholic fatty pancreas disease.Comment on Thomsen et al. Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study. Diabetes Care 2015;38:1089-1098.Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and its kidney clearance: post-hoc analyses of four clinical trials.Effect of 3 Years of Treatment With Exenatide on Postprandial Glucagon Levels.GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes.Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men.Non-alcoholic fatty liver disease as an independent manifestation of the metabolic syndrome: Results of a US national survey in three ethnic groupsLixisenatide Versus Insulin Glulisine on Fasting and Postbreakfast Systemic Hemodynamics in Type 2 Diabetes Mellitus PatientsSmoking is associated with severity of liver fibrosis but not with histological severity in nonalcoholic fatty liver disease. Results from a cross-sectional studyExenatide improves β-cell function up to 3 years of treatment in patients with type 2 diabetes: a randomised controlled trialGlucagon-like peptide-1 receptor agonist exenatide has no acute effect on MRI-measured exocrine pancreatic function in patients with type 2 diabetes: a randomized trialIncretin-based drugs and renoprotection—is hyperfiltration key?Combining incretin-based drugs and RAAS inhibitors: more cons than pros?Smoking Is Related to Pancreatic Fibrosis in HumansThe renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trialCardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomesHigh Prevalence of Intraductal Papillary Mucinous Neoplasms in Type 2 Diabetes Mellitus Patients
P50
Q35613385-8E23E794-963E-41B9-A7A3-253D329AF66BQ36113842-E2A98751-D4FF-41A0-A2CF-3EFB8DE45862Q36302662-6935A73B-0B8C-4E12-8D62-FC72E54E4A5CQ36919647-90FB82A0-1F27-4828-88D6-574DA552DC24Q36990093-720826DD-E1BE-4F7F-948C-0BE3267ABABBQ37185489-3CC1219C-C615-4D5F-BAC0-09CA4B1A10A9Q37456235-F65A173A-EA3B-4760-AE85-0C3452D120ACQ37838235-655DFC3E-1C78-47EA-8B5D-34D4EC3329AEQ38072616-CDCE62A7-2E67-4A58-9626-6B8E5C11F844Q38174491-639B94D1-C165-41DE-BE8B-938F04EC59BCQ38616170-66A50F35-4878-406B-B452-34C20B908307Q38703292-411FD093-2F84-4E5A-AB74-6C1EF16A095BQ38758454-D7240AC2-25A9-42B8-BF56-3711AE4FAEB7Q39112475-5AB53F48-5401-4E20-9DE8-1EACAEDF1F7EQ39220482-CD679588-C9B5-4E20-B498-C4E65463C5CCQ39253117-8CBF3754-9BA9-423D-9EB2-ED3EED3BA582Q39376348-B522E879-BAE2-47E1-9A50-226567F3A492Q40381711-F7960D25-7797-4EBF-BAFD-29C0E9E005DDQ40415039-CBF0B3FC-5448-494F-B398-9C00203E3CCCQ40581820-814E1AC2-CCFF-4CFA-811C-E65DDFAB9527Q40598164-175F7B92-6084-4846-AA86-37181115CEDDQ41744813-A530657C-AB91-4246-A1E0-6263D8CF33CDQ42314614-D73B24D8-563B-4369-BB6D-46C46FB37E67Q42876414-8B6B053D-E697-4A1B-BC39-7958D406D715Q48166975-5637C2F5-2655-48A0-A054-F442AB21289CQ48227892-8FDF8626-CEA0-4F98-B230-C1F1A0286DDFQ48270788-F3B74E7C-BBAC-45C6-A203-B9CA2B53A6EFQ50225916-BA7DBBD3-F20B-4321-BA68-36CCC30390EAQ53254010-B2F6B681-57BA-485F-8B69-29B2DBF5FBE4Q58647442-2C5F5443-D522-4CD9-A99F-29973372970EQ64355402-BE100427-4158-45CF-8EBA-EDABB2BF84CDQ64355403-9A72D330-BB13-48C7-8784-6B826FE8415FQ64355404-ED8F7674-EC59-46B4-80DA-0201F1E41AF9Q64355405-AD4E675B-4149-4601-A257-FA4A4B9D64A1Q64355407-9CF8E0CB-8E5F-423B-851A-09209BB517AAQ64355408-745C9A33-0D8F-4EA4-A60A-E1B0B43A8A0DQ64355409-DD679F14-D711-4B8C-804E-13E7EC07EFF9Q91614830-540E3BDD-3A14-46AB-8249-1C9D72B69DF6Q91875262-848F9DAD-A1FD-4BE6-90E5-47AF33A7D801Q92123114-162AE90B-E9E2-4426-8046-0A363862233B
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mark M Smits
@ast
Mark M Smits
@en
Mark M Smits
@es
Mark M Smits
@nl
Mark M Smits
@sl
type
label
Mark M Smits
@ast
Mark M Smits
@en
Mark M Smits
@es
Mark M Smits
@nl
Mark M Smits
@sl
prefLabel
Mark M Smits
@ast
Mark M Smits
@en
Mark M Smits
@es
Mark M Smits
@nl
Mark M Smits
@sl
P1053
E-6573-2014
P106
P21
P31
P3829
P496
0000-0001-8236-8842